Lecanemab: Fc-Driven Microglial Plaque Clearance vs. Modest Clinical Gain and ARIA Risk
Lecanemab’s main action depends on its Fc fragment calling microglia into action: recent work from VIB and KU Leuven shows…
Evidence-based foods that raise or lower chronic inflammation — and when to adjust
Diet can meaningfully change low‑grade, chronic inflammation: some everyday foods consistently raise inflammatory markers, while others lower them. This guide…
Weekly injectable extended‑release buprenorphine increased prenatal opioid abstinence and reduced serious maternal adverse events
An NIH‑supported randomized trial of 140 pregnant adults with opioid use disorder found that weekly injectable extended‑release buprenorphine produced higher…
24-minute AI-personalized music with binaural beats reduced moderate anxiety in medicated adults in randomized trials
Randomized trials find that a single 24-minute session of AI-personalized music with embedded auditory beat stimulation (ABS) meaningfully lowers anxiety…
Melatonin for Kids: Useful in Specific Cases, Risky as a Routine Fix
Melatonin can help some children—especially those with neurodevelopmental disorders or clear circadian shifts—but product variability, rising accidental exposures, and sparse…
Smart Underwear finds people pass gas about 32 times a day — should clinicians stop trusting self-reports?
University of Maryland researchers have built a wearable they call “Smart Underwear” that continuously measures hydrogen in expelled intestinal gas…
Months to years after severe COVID or flu hospitalization: new UVA evidence ties severe lung infection to higher lung cancer risk — vaccination reverses the signal
New research from the University of Virginia (UVA) links severe respiratory viral infections that require hospitalization to a later rise…
After two months: what POM Wonderful’s early antioxidant gains look like — and why sugar forces limits
POM Wonderful pomegranate juice delivers concentrated antioxidants that can produce measurable benefits in the short term, but an 8-ounce serving…
Salanersen’s Phase 1b: a clear biomarker and motor signal in post–gene‑therapy SMA—Phase 3 will test whether it changes care
Biogen’s Phase 1b results for salanersen showed a pronounced drop in a neurodegeneration biomarker and measurable motor gains in children…
FLOW trial: Sulthiame produced dose-dependent 16–35% AHI reductions — a pharmacologic option for CPAP‑intolerant OSA patients
Sulthiame, an oral carbonic anhydrase inhibitor, cut apnea events in the FLOW Phase 2 trial by roughly 16–35% depending on…